Announcements
- ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
- ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
- ProQR Announces Year End 2023 Operating and Financial Results
- ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
- ProQR Announces Third Quarter 2023 Operating and Financial Results
- ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
More ▼
Key statistics
As of last trade ProQR Therapeutics NV (0PQ:BER) traded at 1.87, -27.15% below its 52-week high of 2.56, set on Jan 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.87 |
---|---|
High | 1.87 |
Low | 1.87 |
Bid | 1.87 |
Offer | 1.93 |
Previous close | 1.83 |
Average volume | 0.00 |
---|---|
Shares outstanding | 81.35m |
Free float | 63.11m |
P/E (TTM) | -- |
Market cap | 162.71m USD |
EPS (TTM) | -0.3699 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 07:04 BST.
More ▼